机构：[1]Peking University People's Hospital, Beijing[2]Pingxiang People's Hospital, Pingxiang[3]Renji Hospi. Affliated to SH Jiaotong U, Shanghai[4]Qilu Hospital of Shandong University, Shandong[5]Anhui Provincial Hospital[6]1st Affiliate Hospital of AnHui Med U, Anhui, China[7]Centro Medico Privado de Reumatologica, Tucuman, Argentina[8]Guangdong General Hospital, Guangdong广东省人民医院[9]1st Affiliated Hospital of Kunming Med U, Kunming昆明医科大学附属第一医院[10]1st Afflilated Hospital of Bengbu Med C, Anhui[11]China-Japan Friendship Hospital, Beijing[12]Eli Lilly and Company, Shanghai, China[13]Eli Lilly and Company, Indianapolis, United States[14]Centro Paulista de Investigacao Clinica, São Paulo, Brazi
第一作者机构：[1]Peking University People's Hospital, Beijing
推荐引用方式(GB/T 7714)：
Z. Li,J. Hu,C. Bao,et al.EFFICACY AND SAFETY OF BARICITINIB IN MTX-IR PATIENTS WITH RHEUMATOID ARTHRITIS: 52 WEEK RESULTS FROM A PHASE 3 STUDY (RA-BALANCE)[J].ANNALS OF THE RHEUMATIC DISEASES.2018,77:969-970.doi:10.1136/annrheumdis-2018-eular.1983.
APA：
Z. Li,J. Hu,C. Bao,X. Li,X. Li...&C. Zerbini.(2018).EFFICACY AND SAFETY OF BARICITINIB IN MTX-IR PATIENTS WITH RHEUMATOID ARTHRITIS: 52 WEEK RESULTS FROM A PHASE 3 STUDY (RA-BALANCE).ANNALS OF THE RHEUMATIC DISEASES,77,
MLA：
Z. Li,et al."EFFICACY AND SAFETY OF BARICITINIB IN MTX-IR PATIENTS WITH RHEUMATOID ARTHRITIS: 52 WEEK RESULTS FROM A PHASE 3 STUDY (RA-BALANCE)".ANNALS OF THE RHEUMATIC DISEASES 77.(2018):969-970
医学